ReviewWorld journal of hepatology2019
Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.
Review in World journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05042024 (Supplementation With L-ornithine Increases Representation Density of CD68+ and CD163+ Macrophages in Human Periodontitis Gingiva and Can Modulate Macrophages Phenotypes. Randomized Controlled Pilot Trial), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Supplementation With L-ornithine Increases Representation Density of CD68+ and CD163+ Macrophages in Human Periodontitis Gingiva and Can Modulate Macrophages Phenotypes. Randomized Controlled Pilot Trial
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- Effect of a specificWorld journal of hepatology · 2022Trial
- Integrated multiomics analysis reveals metabolic and microbiome alterations in Wilson disease.iScience · 2026Article
- The Liver-brain Axis: A Three-stage Model Linking MASLD to Cognitive Impairment and Dementia.Journal of molecular neuroscience : MN · 2026Review
- Unraveling the Complexities of Small Intestinal Bacterial Overgrowth.Medicina (Kaunas, Lithuania) · 2026Review
- Gut microbiome and bile acid metabolism in liver disease: Mechanisms, clinical implications, and therapeutic opportunities.Pharmacological reviews · 2026Review
- [Assessment and management of malnutrition in patients with cirrhosis combined with hepatic encephalopathy].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Unraveling the Gut-Liver-Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches.Mediators of inflammation · 2025Review
- Does Gut Microbiome have an Effect on Wilson's Disease Phenotype?Current medicinal chemistry · 2025Article
- A Comprehensive Review of the Usefulness of Prebiotics, Probiotics, and Postbiotics in the Diagnosis and Treatment of Small Intestine Bacterial Overgrowth.Microorganisms · 2025Review
- Li-Hong Tang alleviates dextran sodium sulfate-induced colitis by regulating NRF2/HO-1 signaling pathway and gut microbiota.Frontiers in pharmacology · 2024Article
- The pathogenesis of gut microbiota in hepatic encephalopathy by the gut-liver-brain axis.Bioscience reports · 2023Article
- Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease.Metabolites · 2023Review
- Yeast Cell Wall Compounds on The Formation of Fermentation Products and Fecal Microbiota in Cats: An In Vivo and In Vitro Approach.Animals : an open access journal from MDPI · 2023Article
- Treating Leaky Syndrome in the Over 65s: Progress and Challenges.Clinical interventions in aging · 2023Article
- Liver cirrhosis and complications from the perspective of dysbiosis.Frontiers in medicine · 2023Review
- Gut commensals and their metabolites in health and disease.Frontiers in microbiology · 2023Review
- Host-microbiome interactions: Gut-Liver axis and its connection with other organs.NPJ biofilms and microbiomes · 2022Review
- The Link between Gut Microbiota and Hepatic Encephalopathy.International journal of molecular sciences · 2022Review
- Mechanisms of Zhenwu decoction for the treatment of renal fibrosis at various stages: What is the role ofFrontiers in microbiology · 2022Article
- Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory.Contrast media & molecular imaging · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic encephalopathy (HE) is a common and serious neuropsychiatric complication of cirrhosis, acute liver failure, and porto-systemic shunting. HE largely contributes to the morbidity of patients with liver disease, severely affecting the quality of life of both patients and their relatives and being associated with poor prognosis. Its presentation is largely variable, manifesting with a broad spectrum of cognitive abnormalities ranging from subtle cognitive impairment to coma. The pathogenesis of HE is complex and has historically been linked with hyperammonemia. However, in the last years, it has become evident that the interplay of multiple actors, such as intestinal dysbiosis, gut hyperpermeability, and neuroinflammation, is of crucial importance in its genesis. Therefore, HE can be considered a result of a dysregulated gut-liver-brain axis function, where cognitive impairment can be reversed or prevented by the beneficial effects induced by "gut-centric" therapies, such as non-absorbable disaccharides, non-absorbable antibiotics, probiotics, prebiotics, and fecal microbiota transplantation. In this context dietary modifications, by modulating the intestinal milieu, can also provide significant benefit to cirrhotic patients with HE. This review will provide a comprehensive insight into the mechanisms responsible for gut-liver-brain axis dysregulation leading to HE in cirrhosis. Furthermore, it will explore the currently available therapies and the most promising future treatments for the management of patients with HE, with a special focus on the dietary approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.